Canada: New Decision on Freedom of Information Re: Product Listing Agreements

On June 28, 2010, the Information and Privacy Commissioner of Ontario released a decision in Appeal Number PA08-294-2, which pertains to disclosure of Schedules to a product listing agreement between an unidentified drug company (the "affected party") and the Executive Officer of the Ontario Public Drug Programs ("OPDP"). The Information and Privacy Commissioner Adjudicator determined that the Schedules, which contain information relating to the drug benefit price, calculation of volume discount, and terms and conditions of listing, are exempt from disclosure.

Unlike in three previous orders issued in January 2010, also in respect of information relating to product listing agreements, the affected party was given notice by the Information and Privacy Commissioner of the appeal. However, the Adjudicator held that it was unnecessary to consider the affected party's submissions that the third party exemption in section 17(1) of the Freedom of Information and Protection of Privacy Act ("FIPPA") applied to the Schedules, given her determination that the Schedules were exempt from disclosure pursuant to section 18(1) of the FIPPA, which applies to information the disclosure of which would cause financial or other harm to a government institution.

Background to the Appeal before the Information Commissioner

By way of background, the original request was for copies of all pricing agreements between the OPDP and drug manufacturers since October 1, 2006. The Ontario Ministry of Health and Long-Term Care ("Ministry") did not notify the affected drug manufacturers of the request, but indicated to the requester (whose identity is unknown) that access to the agreements would be granted with severances made pursuant to section 18(1) on payment of a fee. The requester appealed the fee to the Information and Privacy Commissioner of Ontario.

During mediation between the requester/appellant and the Ministry, the request was narrowed to include agreements relating to only six drug manufacturers. Also during mediation, the Ministry provided the requester/appellant with a representative sample of a final listing agreement with a named drug company (the affected party). Only the Schedules to the sample agreement were severed. The requester/appellant advised the mediator that he wished to pursue access to the withheld Schedules to the sample agreement, but would not pursue access to the severed information in the agreements relating to the other five companies.

The affected party was notified of the appeal and filed its own appeal seeking a declaration that it was unlawful for the Ministry to have released the agreement in severed format without having provided prior notice to the affected party. The decision indicates that this appeal has been placed on hold pending judicial review proceedings of Orders PO-2863, PO-2864 and PO-2865 (issued January 13, 2010), which deal with a similar issue.

Both the affected party, and the innovative industry association, Rx&D, made representations objecting to the disclosure of the Schedules at issue in the appeal brought by the requester/appellant.

The Government's Interests Would be Harmed by Disclosure

The Adjudicator held that the Ministry's exemption in section 18(1) of FIPPA applies such that the Schedules to the product listing agreement are exempt from disclosure. Consistent with the rationale set out in Order PO-2865 (issued January 13, 2010), the Adjudicator held:

Based on my review of the records, I agree with the Ministry that disclosure of the information at issue in the records could reasonably be expected to attract the harms contemplated in sections 18(1)(c) and (d). The information at issue reveals how much a named manufacturer has agreed to pay the Ministry by way of a volume discount amount for a particular drug, as well as what other specific financial and value for money conditions the manufacturer agreed to provide to the Ministry. This information could be used by other potential bulk prescription drug purchasers as a discount standard or price goal to be obtained form the drug manufacturers.

I find that disclosure of the information at issue could reasonably be expected to discourage drug manufacturers in the future from negotiating large volume discounts and other favourable financial terms with Ontario, out of concern that this information could be used by their other public and private sector customers seeking to negotiate similar discounts with the drug manufacturers [Orders PO-2863 and PO-2786]. Furthermore, other drug manufacturers would expect Ontario to negotiate a lower volume discount in the future for their drugs, if it is revealed that Ontario was willing to negotiate a lesser discount for a similar drug with another drug manufacturer. I find that disclosure of the information at issue could reasonably be expected to seriously prejudice the Ministry's ability to secure savings on prescription drugs by weakening its bargaining position in negotiations with manufacturers [Oder PO-2780].

The Public Interest in Disclosure

The Adjudicator rejected the requester/appellant's argument that there exists a compelling interest in disclosure of the Schedules that outweighs the purpose of the section 18(1) exemption. The Adjudicator quoted the representations made by the affected third party and Rx&D on the issue of whether it was in the public interest to release the information, including the following submissions made by Rx&D:

There is no public harm in refusing to disclose the information that is at issue. Indeed, Rx&D suspects that there would be significant public harm in disclosing the information, as Canada would be out of step with other jurisdictions in their practices, as Rx&D understands them to be, relating to the disclosure of this commercial and highly sensitive information. Rx&D further believes that if such information is disclosed, there is significant risk for Ontario that there would be higher prices for products, and fewer product listings, resulting in less access to needed drugs by patients. . .

Pricing and market access are issues of great importance to the innovative industry represented by Rx&D. If information that was clearly submitted to the Ontario government in confidence and with the expectation that it would be held in confidence were now disclosed, Rx&D submits this would be devastating for the industry, and would affect the investment climate with a negative effect on its members. Confidence in both Ontario and Canada as a place to do business would decline, with the resulting uncertainty and potential job losses.

In the result, the Adjudicator held, on the issue of the public interest, that:

Although the appellant claims that the volume discounts scheme leaves many in Ontario on private plans and without coverage paying higher drug prices, I am not satisfied that even if this is the case that disclosure of the information at issue would significantly aid in remedying this situation. The information in issue reveals how much the Ontario government pays for a particular drug purchased in bulk from a drug manufacturer for its ODB program. This pricing information does not relate to the pricing of the same drug purchased by private interests.

The information sought to be disclosed in the context of this appeal is not relevant to public health and safety, which is monitored by the drug approval process. In the circumstances of this appeal, the relevant decision making body, the ODB Program has full disclosure of all relevant information required to make the listing decision for the specific drug named in the records, including the recommendations received by CDR regarding clinical and cost effectiveness. I agree with the Ministry that it has provided sufficient information to satisfy whatever public interest may exist in this agreement, without revealing information that both the Executive Officer and the affected party, the drug manufacturer, consider highly confidential.

"... the information already disclosed serves to inform the public about many of the specifics of listing agreements. The only information severed from the listing agreement is the schedules which contain information as to the negotiated volume discount amount and the conditions of listing the specific drug product."

For a copy of the decision, see: Order PO-2898

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.